When should treatment be stopped?
The open questions surrounding immunotherapy and targeted therapy in lung cancer
Preventing prostate cancer mortality through population based screening
Hendrik Van Poppel
Exciting advances in systemic therapy for prostate cancer: docetaxel and abiraterone
What are the next steps for screening programms for the detection of distress in cancer patients?